• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 11-K filed by Cencora Inc.

    6/17/25 4:33:24 PM ET
    $COR
    Other Pharmaceuticals
    Health Care
    Get the next $COR alert in real time by email
    11-K 1 a11-kxdecember312024.htm 11-K Document


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C.  20549
     
    FORM 11-K
     
    x                   ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the fiscal year ended December 31, 2024
     
    OR
     
    o                  TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
     
    For the transition period from                            to                                                     
     
    Commission file number 001-16671
     
    CENCORA EMPLOYEE INVESTMENT PLAN
    (Full title of the plan)
     
    CENCORA, INC.
    (Name of issuer of the securities held pursuant to the plan)
     
    1 West First Avenue, Conshohocken, PA 19428-1800
    (Address of principal executive offices of issuer of securities) (Zip code)










    Cencora Employee Investment Plan
    Financial Statements and Supplemental Schedule
    December 31, 2024 and 2023 and for the year ended December 31, 2024






    TABLE OF CONTENTS
    Report of Independent Registered Public Accounting Firm
    1
    Audited Financial Statements
    Statements of Net Assets Available for Benefits
    2
    Statement of Changes in Net Assets Available for Benefits
    3
    Notes to Financial Statements
    4
    Supplemental Schedule and Additional Information
    Schedule of Assets (Held at End of Year)
    9
    Exhibit
    10
    Signature
    11





        



    Table of Contents
    Report of Independent Registered Public Accounting Firm

    To the Plan Participants and the Plan Administrator of Cencora Employee Investment Plan
    Opinion on the Financial Statements
    We have audited the accompanying statements of net assets available for benefits of Cencora Employee Investment Plan (the Plan) as of December 31, 2024 and 2023, and the related statement of changes in net assets available for benefits for the year ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan at December 31, 2024 and 2023, and the changes in its net assets available for benefits for the year ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.
    Basis for Opinion
    These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
    We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.
    Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
    Supplemental Schedule Required by ERISA
    The accompanying supplemental schedule of assets (held at end of year) as of December 31, 2024 (referred to as the “supplemental schedule”), has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The information in the supplemental schedule is the responsibility of the Plan’s management. Our audit procedures included determining whether the information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental schedule. In forming our opinion on the information, we evaluated whether such information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

    /s/ Ernst & Young LLP

    We have served as the Plan's auditor since 1986.
    Philadelphia, Pennsylvania
    June 17, 2025





    1

    Table of Contents
    Cencora Employee Investment Plan
    Statements of Net Assets Available for Benefits

    As of December 31,
    20242023
    Assets
    Investments at fair value
    Registered investment companies$67,491,333 $449,271,951 
    Common collective trust funds514,081,762 75,786,115 
    Commingled funds1,389,307,804 1,205,978,427 
    Common stock fund81,113,550 82,621,049 
    Investments at contract value— 127,522 
    Total investments2,051,994,449 1,813,785,064 
    Receivables
    Notes receivable from participants32,206,946 28,733,189 
    Employer contributions15,590,809 13,239,861 
    Other receivables507,354 — 
    Total receivables48,305,109 41,973,050 
    Net assets available for benefits$2,100,299,558 $1,855,758,114 

    See accompanying notes.
    2

    Table of Contents
    Cencora Employee Investment Plan
    Statement of Changes in Net Assets Available for Benefits

    Year Ended December 31, 2024
    Changes to net assets attributed to investment income:
    Interest and dividend income$9,371,116 
    Net appreciation in fair value of investments267,338,338 
    Total investment income276,709,454 
    Interest income on notes receivable from participants1,258,649 
    Contributions:
    Participant110,438,615 
    Employer62,504,872 
    Rollover13,047,468 
    Total contributions185,990,955 
    Benefits paid to participants(218,406,513)
    Administrative expenses(1,011,101)
    Net increase in net assets available for benefits244,541,444 
    Net assets available for benefits:
    Beginning of year1,855,758,114 
    End of year$2,100,299,558 

    See accompanying notes.




    3

    Table of Contents
    Cencora Employee Investment Plan
    Notes to Financial Statements
    December 31, 2024

    NOTE 1 - DESCRIPTION OF PLAN
    The following description of the Cencora Employee Investment Plan (the "Plan") provides only general information. Participants should refer to the Plan Document for a complete description of the Plan's provisions. In January 2024, the Plan's name was changed from the AmerisourceBergen Employee Investment Plan to the Cencora Employee Investment Plan.
    General
    The Plan is a defined contribution plan that covers eligible employees of Cencora, Inc. and affiliated companies (collectively, the "Company" or "Employer"), who have at least 30 days of continuous employment. If not already enrolled, eligible full-time employees are automatically enrolled in the Plan on the first day of the first payroll period that coincides with, or the next payroll period following, the date that represents 90 days of continuous employment (30 days of continuous employment for rehired participants who had previously met the eligibility requirements) unless they waive participation. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974, as amended ("ERISA"). The Company's Benefits Committee is responsible for the general administration of the Plan.
    Contributions
    Each year, participants are entitled to make pre-tax deferral or Roth contributions from 1% to 50% of their eligible compensation, up to the annual Internal Revenue Service ("IRS") contribution limit. The Company contributes to the Plan for each participating employee an amount equal to 100% of the participant's contributions up to 3% and 50% on the next 2% of the participant's eligible contributions. If automatically enrolled, a participant's deferral is set at a 5% pretax contribution rate of eligible compensation until changed by the participant. The automatic deferral percentage increases by 1% each year on the anniversary date of the participant's automatic enrollment date but will not exceed 10% of compensation. Participants who have attained age 50 before the end of the year are eligible to make catch-up contributions. Participants may also contribute amounts representing distributions and/or transfers from other qualified defined benefit or defined contribution plans. All contributions are subject to certain limitations of the Internal Revenue Code ("IRC"). The Plan also includes a Roth feature and a Roth conversion feature.
    At the discretion of the Company, additional amounts may be contributed to each eligible participating employee's account annually. The Company approved $11,800,220 of discretionary contributions for the 2024 Plan year, which is included in Employer Contributions on the Statement of Net Assets Available for Benefits as of December 31, 2024.
    Upon enrollment, a participant may direct the investment of employee and employer contributions to any of the Plan's fund options. However, effective January 1, 2018, no new contributions under the Plan or amounts in an existing account under the Plan shall be invested in the Cencora Stock Fund, and cash dividends paid on Cencora, Inc.'s stock will be invested in accordance with the individual participant's investment allocations for new contributions as of the dividend payment date. Participants may change their investment options at any time. Participants that are automatically enrolled have their initial contributions invested in a Fidelity Freedom Blend Commingled Pool Class T retirement date fund based upon their anticipated retirement dates until they change their election. The Company's contributions are invested in the same manner as that of the participant's elective contributions.
    Participant Accounts
    A separate account is maintained for each investment option of a participant by type of contribution. Each participant's account is credited with the participant's contributions and the Company's contributions and allocations of Plan earnings and is charged with the investment fund's underlying administrative expenses. Plan earnings are allocated based upon the participant's share of net earnings or losses of their respective elected investment options. Allocations of administrative expenses are based on the participant's account balances, as defined in the Plan's provisions. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

    4


    Vesting
    Participants immediately vest in their own contributions and actual earnings or losses thereon. In addition, participants are immediately vested in their Company matching contributions and actual earnings or losses thereon, except for certain participants merged into the Plan whose former matching contributions continue to vest according to the predecessor plan's vesting provisions.
    The vesting of the Company's discretionary contributions, if any, is based on a graded schedule as follows:
    Years of ServiceVested Percentage
    Less than 2 years0%
    2 years but less than 3 years25%
    3 years but less than 4 years50%
    4 years but less than 5 years75%
    5 years or more100%
    Notes Receivable from Participants
    Participants may borrow from their fund accounts a minimum of $1,000 up to a maximum equal to the lesser of $50,000, reduced by the highest outstanding loan balance in the last twelve months, or 50% of their vested account balance. This amount will be transferred from the participant's account and placed in a separate participant loan fund. Interest charged on participant loans is credited to the individual participant accounts.
    The term of the loan may not exceed five years unless it qualifies as a primary residence loan, in which case the loan may not exceed ten years. A participant may not have more than one loan outstanding at any point in time, and a participant must wait at least three months following repayment in full of the prior loan before applying for a new loan. Participant loans are collateralized by the vested balance in the participant's account and bear interest at the Prime Rate (as determined by the Plan administrator as of the date the loan is processed), plus one percent. Foreclosure on defaulted participant loans does not occur until a distributable event, as defined in the Plan, occurs. Principal and interest are paid through payroll deductions. As of December 31, 2024 and 2023, participant loans are shown as a receivable of the Plan. Interest rates on loans outstanding as of December 31, 2024 ranged from 4.25% to 5.00%.
    Payment of Benefits
    Upon termination of service, death, disability, or retirement, the vested portion of a participant's account, less any loans outstanding, may be distributed in a lump sum or, in certain defined situations, in annual installments. Participants who terminate employment on or after attainment of age 55 are permitted to take installment distributions of their vested plan benefits. A participant whose vested account balance is $1,000 or less shall immediately receive the entire vested account balance. In addition, hardship withdrawals are permitted if certain criteria are met. Hardship withdrawals do not require a suspension of contributions to the Plan.
    Forfeited Accounts
    If participants separate from service before becoming fully vested in their accounts, the portion of the account attributable to nonvested Employer discretionary contributions and predecessor plans, plus/minus actual earnings or losses thereon is not forfeited until the earlier of the date the participant receives a distribution or the date the participant incurs a five-year break in service. Forfeited balances of terminated participants' nonvested accounts are used to reduce future Company contributions. During the year ended December 31, 2024, Employer matching contributions were reduced by $1,619,486 from forfeited nonvested accounts. Forfeited nonvested balances totaled $36,596 and $9,199 as of December 31, 2024 and 2023, respectively.
    Administrative Expenses
    The Plan's administrative expenses are paid by either the Plan or the Company, as provided by the Plan's provisions. Administrative expenses paid by the Plan include recordkeeping and trustee fees. Expenses relating to purchases, sales, and transfers of the Plan's investments are charged to the particular investment fund to which the expenses relate. Participants pay recordkeeping fees that are deducted from their accounts quarterly. All other administrative expenses of the Plan are paid by the Company and are excluded from these financial statements.

    5


    Plan Termination
    Although it has not expressed any intent to do so, the Company has the right under the Plan to discontinue its contributions at any time and to terminate the Plan subject to the provisions of ERISA. In the event of Plan termination, the Plan's net assets available for benefits, after Plan expenses, will be distributed to each participant according to his or her account balance, which will fully vest immediately.
    SECURE 2.0 Act
    On December 29, 2022, the SECURE 2.0 Act was signed into law by President Biden as part of the Consolidated Appropriations Act of 2023. The Plan has been updated with the required changes, including increasing the limit for employers to transfer former employees’ retirement accounts from the Plan into an IRA for certain distributions made after December 31, 2023, increasing the mandatory distribution age starting on January 1, 2023, and providing additional options for surviving spouses.
    NOTE 2 - RISKS AND UNCERTAINTIES
    The Plan invests in various investment securities. Investment securities are exposed to various risks, such as interest rate and market and credit risks. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the statements of net assets available for benefits.
    NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    Basis of Accounting
    The accompanying financial statements have been prepared on the accrual basis in accordance with U.S. generally accepted accounting principles ("GAAP").
    Use of Estimates
    The preparation of financial statements, in conformity with GAAP, requires management to make estimates that affect the amounts reported in the financial statements, accompanying notes, and supplemental schedule. Actual results could differ from those estimates.
    Investment Valuation and Income Recognition
    The Plan's investments (except for fully benefit-responsive investment contracts) are stated at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). See Note 4 for further discussion and disclosures related to fair value measurements. Fully benefit-responsive investment contracts were reported at contract value and were liquidated during 2024.
    Shares of registered investment companies are quoted at market prices, which represent the net asset value of shares held by the Plan at the end of the year. Participant transactions (purchases and sales) of the commingled funds and the common collective trust fund may occur daily as both types of funds have readily determinable fair values. The Cencora Stock Fund is valued at its year-end closing price.
    Purchases and sales of investments are recorded on a trade-date basis. Interest income is accrued when earned. Dividend income is recorded on the ex-dividend date. Capital gain distributions are recorded as a component of dividend income. Net appreciation (depreciation) includes the Plan's gains and losses on investments bought and sold, as well as held, during the year.
    Payment of Benefits
    Benefits are recorded when paid.
    Notes Receivable from Participants
    Notes receivable from participants represent participant loans that are recorded at their unpaid principal balance, plus any accrued but unpaid interest. If a participant ceases to make loan repayments and the Plan administrator deems the participant loan to be a distribution, the participant loan balance is reduced and a benefit payment is recorded. Interest income on notes receivable from participants is recorded when it is earned. Participants pay administrative fees upon request of a loan and throughout the duration of the repayment period. The Company's reserves for participant loans that were deemed uncollectible were $405,131 and $373,757 as of December 31, 2024 and 2023, respectively.

    6




    NOTE 4 - FAIR VALUE MEASUREMENTS
    In accordance with ASC 820, Fair Value Measurements and Disclosures, assets and liabilities measured at fair value are categorized into the following fair value hierarchy:
    Level 1    Financial assets and liabilities whose values are based on unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
    Level 2    Financial assets and liabilities whose values are based on the following:
    a)Quoted prices for similar assets or liabilities in active markets;
    b)Quoted prices for identical or similar assets or liabilities in non-active markets;
    c)Pricing models whose inputs are observable for substantially the full term of the asset or liability; and
    d)Pricing models whose inputs are derived principally from or corroborated by observable market data through correlation or other means for substantially the full term of the asset or liability.
    Level 3    Financial assets and liabilities whose values are based on prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable. These inputs reflect management's own judgment about the assumptions that a market participant would use in pricing the asset or liability.
    The level in the fair value hierarchy within which the fair value measurement is classified is determined based on the lowest level of input that is significant to the fair value measure in its entirety.
    Below are the Plan's financial instruments carried at fair value on a recurring basis by their ASC 820 fair value hierarchy levels:
    Assets at Fair Value as of December 31, 2024
    Level 1Level 2Level 3Total
    Registered investment companies$67,491,333 $— $— $67,491,333 
    Common collective trust funds514,081,762 — — 514,081,762 
    Commingled funds1,389,307,804 — — 1,389,307,804 
    Common stock fund81,113,550 — — 81,113,550 
    Investments at fair value$2,051,994,449 $— $— $2,051,994,449 
    Assets at Fair Value as of December 31, 2023
    Level 1Level 2Level 3Total
    Registered investment companies$449,271,951 $— $— $449,271,951 
    Common collective trust fund75,786,115 — — 75,786,115 
    Commingled funds1,205,978,427 — — 1,205,978,427 
    Common stock fund82,621,049 — — 82,621,049 
    Investments at fair value$1,813,657,542 $— $— $1,813,657,542 
    NOTE 5 - RELATED PARTY AND PARTY-IN-INTEREST TRANSACTIONS
    The Plan invests in shares of registered investment companies, commingled funds, and common collective trust funds managed by an affiliate of Fidelity Management Trust Company ("Fidelity"). Fidelity acts as trustee for investments in the Plan. Transactions in such investments qualify as party-in-interest transactions and are exempt from the prohibited transaction rules under ERISA.
    The Plan held investments in Cencora, Inc. common stock with a fair value of $81,113,550 and $82,621,049 as of December 31, 2024 and 2023, respectively. Dividends of $795,783 were received during the year ended December 31, 2024.
    NOTE 6 - TAX STATUS
    The Plan received a determination letter from the IRS, dated May 20, 2020, stating that the Plan was qualified under Section 401(a) of the IRC and, therefore, the related trust is exempt from taxation. Once qualified, the Plan is required to operate in conformity with the IRC to maintain its qualification. The Plan administrator has indicated that it will take the necessary steps, if any, to bring the Plan’s operations into compliance with the Code.
    7


    GAAP requires plan management to evaluate uncertain tax positions taken by the Plan. The financial statement effects of a tax position are recognized when the position is more likely than not, based on the technical merits, to be sustained upon examination by the IRS. The Company has analyzed the tax positions taken by the Plan, and has concluded that, as of December 31, 2024, there are no uncertain positions taken or expected to be taken. The Plan has recognized no interest or penalties related to uncertain tax positions. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress.
    NOTE 7 - RECONCILIATION OF FINANCIAL STATEMENTS TO FORM 5500
    The following is a reconciliation of net assets available for benefits per the financial statements to Form 5500:
    December 31,
    20242023
    Net assets available for benefits per the financial statements$2,100,299,558 $1,855,758,114 
    Participant loans deemed distributed(101,758)(128,044)
    Net assets available for benefits per Form 5500$2,100,197,800 $1,855,630,070 
    The following is a reconciliation of the net increase in net assets available for benefits per the financial statements to net income per Form 5500:
    Net increase in net assets available for benefits per the financial statements$244,541,444 
    Change in amounts for deemed distributions of participant loans26,286 
    Net income per Form 5500$244,567,730 

    8


    Cencora Employee Investment Plan
    EIN: 23-3079390 Plan #: 010
    Schedule H, line 4i - Schedule of Assets (Held at End of Year)
    December 31, 2024
    Identity of Issue, Borrower, Lessor, or Similar PartyDescription of Investment, Including Maturity Date, Rate of Interest, Collateral, Par or Maturity ValueCurrent Value
    American Funds EuroPacific Growth Fund Class R-6Registered Investment Company$19,432,547 
    JPMorgan Equity Income Fund Class R6Registered Investment Company48,058,786 
    *Fidelity Growth Company Commingled Pool Class ACommingled Fund283,979,647 
    *Fidelity Freedom Blend 2010 Commingled Pool Class TCommingled Fund4,849,799 
    *Fidelity Freedom Blend 2015 Commingled Pool Class TCommingled Fund7,807,330 
    *Fidelity Freedom Blend 2020 Commingled Pool Class TCommingled Fund38,011,084 
    *Fidelity Freedom Blend 2025 Commingled Pool Class TCommingled Fund80,198,125 
    *Fidelity Freedom Blend 2030 Commingled Pool Class TCommingled Fund151,524,513 
    *Fidelity Freedom Blend 2035 Commingled Pool Class TCommingled Fund187,218,911 
    *Fidelity Freedom Blend 2040 Commingled Pool Class TCommingled Fund185,145,455 
    *Fidelity Freedom Blend 2045 Commingled Pool Class TCommingled Fund163,973,928 
    *Fidelity Freedom Blend 2050 Commingled Pool Class TCommingled Fund130,284,640 
    *Fidelity Freedom Blend 2055 Commingled Pool Class TCommingled Fund94,243,913 
    *Fidelity Freedom Blend 2060 Commingled Pool Class TCommingled Fund53,040,049 
    *Fidelity Freedom Blend Income Commingled Pool Class TCommingled Fund9,030,410 
    Western Asset Core Plus Bond Fund - Class R3Common Collective Trust Fund25,343,457 
    Westwood SMidCap Value Collective Trust Class CCommon Collective Trust Fund45,925,032 
    State Street US Bond Index Securities Lending Fund Class XIVCommon Collective Trust Fund17,885,088 
    State Street Global All Cap Equity Ex-US Index Securities Lending Series Fund Class IICommon Collective Trust Fund13,998,100 
    State Street Russell Small/Mid Cap Securities Lending Series Fund Class IICommon Collective Trust Fund52,344,550 
    State Street S&P 500 Index Securities Lending Series Fund Class IICommon Collective Trust Fund231,848,560 
    Kayne Anderson Rudnick Small-Mid Cap Sustainable Growth CIT Class 1Common Collective Trust Fund53,754,345 
    *Fidelity Managed Income Portfolio II Class 4Common Collective Trust Fund72,982,630 
    *Cencora Stock FundCommon Stock Fund81,113,550 
    *Participant Loans
    Interest rates ranging from 4.25% to 5.00%
    32,105,188 
    Total$2,084,099,637 
    ___________________________
    * Party-in-interest

    Note: Cost information has not been presented as all investments are participant directed.
    9


    Exhibit NumberDescription
    23
    Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

    10


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the Plan) have duly caused this annual report to be signed on its behalf by the undersigned thereunto duly authorized.

    Cencora Employee Investment Plan
    June 17, 2025/s/ Silvana Battaglia
    Silvana Battaglia
    Executive Vice President and Chief Human Resources Officer
    Cencora, Inc.




    11
    Get the next $COR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $COR

    DatePrice TargetRatingAnalyst
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    12/4/2024$280.00Outperform
    Mizuho
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    2/26/2024$261.00Outperform
    Leerink Partners
    1/3/2024$242.00Overweight
    Barclays
    12/14/2023$213.00Equal Weight
    Wells Fargo
    12/14/2021$162.00 → $170.00Buy → Neutral
    Citigroup
    11/26/2021$136.00 → $170.00Sector Perform
    RBC Capital
    More analyst ratings

    $COR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the c

      7/3/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Elects Lori J. Ryerkerk to Its Board of Directors

      Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. "Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value," said Mark Durcan, Lead Independent Director. "Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and bu

      5/28/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    SEC Filings

    See more
    • Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      7/3/25 4:01:37 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form 11-K filed by Cencora Inc.

      11-K - Cencora, Inc. (0001140859) (Filer)

      6/17/25 4:33:24 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Cencora, Inc. (0001140859) (Filer)

      6/6/25 4:01:51 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cencora upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00

      6/3/25 7:24:57 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Mizuho resumed coverage on Cencora with a new price target

      Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

      12/4/24 7:30:44 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora downgraded by BofA Securities with a new price target

      BofA Securities downgraded Cencora from Buy to Neutral and set a new price target of $245.00 from $275.00 previously

      9/18/24 8:27:47 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/29/24 4:02:27 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Vice President Campbell Elizabeth S was granted 46 shares, increasing direct ownership by 0.31% to 14,710 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      7/7/25 4:44:50 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Executive Vice President Battaglia Silvana was granted 53 shares, increasing direct ownership by 0.47% to 11,349 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      7/7/25 4:02:37 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Director Ryerkerk Lori was granted 516 shares (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      7/2/25 4:01:11 PM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Financials

    Live finance-specific insights

    See more
    • Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the c

      7/3/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    Leadership Updates

    Live Leadership Updates

    See more
    • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

      Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

      11/4/24 8:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

      The communications industry veteran brings years of experience to NWS Network Wireless Solutions, LLC ("NWS"), a rapidly growing solutions and logistics provider to carriers and telecommunications contractors, announced today the appointment of Michael Millegan to its board. NWS is a portfolio company of Grain Management, LLC ("Grain"), a leading Washington, D.C.-based investment firm focused on the global communications sector. Mr. Millegan is a seasoned technology executive with several years of experience leading company strategy, including sales, marketing, supply chain operations, cell site build-out, and engineering. Currently, Mr. Millegan serves as an independent board director fo

      9/14/21 2:00:00 PM ET
      $AXS
      $COR
      $POR
      $WTT
      Property-Casualty Insurers
      Finance
      Other Pharmaceuticals
      Health Care

    $COR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cencora Inc.

      SC 13G/A - Cencora, Inc. (0001140859) (Subject)

      11/14/24 1:22:34 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cencora Inc.

      SC 13D/A - Cencora, Inc. (0001140859) (Subject)

      8/5/24 6:43:49 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

      SC 13G/A - CoreSite Realty Corp (0001490892) (Subject)

      7/12/21 8:29:18 AM ET
      $COR
      Other Pharmaceuticals
      Health Care